Market Cap: $1.18B
SI
Syndax Pharmaceuticals, Inc.
SNDX
NASDAQ (NASDAQ Global Select)USD
Market Cap: $1.18B
Syndax Pharmaceuticals (Ticker: SNDX) showcases significant advancements in the treatment of acute myeloid leukemia (AML) with its recently reported Phase 1/2 SAVE trial results. The trial investigate…
Syndax Pharmaceuticals (Ticker: SNDX) makes a significant impact at the ASCO 2026 Annual Meeting by unveiling crucial research on their drug Revuforj (revumenib). The company presents four abstracts t…
Syndax Pharmaceuticals has made a notable announcement regarding its drug Revuforj® (revumenib), confirming that four of its abstracts have been accepted for presentation at the prestigious American S…
Syndax Pharmaceuticals Reports Strong Q4 Earnings, Demonstrating Market Commitment Syndax Pharmaceuticals (NASDAQ: SNDX) releases its Q4 earnings results, showcasing remarkable recovery and strong gro…
Syndax Pharmaceuticals Reports Strong Q4 Earnings and Optimism for Future Growth Syndax Pharmaceuticals continues to demonstrate robust growth in the biopharmaceutical sector, as evidenced by its four…
Syndax Pharmaceuticals: Strong Q4 Performance Signals Growth Potential in Biotech Sector Syndax Pharmaceuticals recently reports its Q4 earnings, showcasing notable progress that enhances its standing…
Syndax Pharmaceuticals Advances Oncology Pipeline Amid Challenging Market Conditions Syndax Pharmaceuticals, a clinical-stage biopharmaceutical company, continues to make significant strides in its on…
Syndax Pharmaceuticals Strengthens Its Position in the Biopharmaceutical Landscape Syndax Pharmaceuticals, a notable player in the biopharmaceutical sector, continues to advance its strategic initiati…
Syndax Pharmaceuticals Prepares for Key Earnings Report Amidst Clinical Developments Syndax Pharmaceuticals gears up for its quarterly earnings report set to be released on November 3, 2025, a pivotal…
Syndax Pharmaceuticals Receives FDA Approval Amid Investor Hesitation Syndax Pharmaceuticals, Inc. achieves a significant milestone with the recent approval from the U.S. Food and Drug Administration…
Syndax Pharmaceuticals: Navigating a Complex Landscape of Analyst Opinions Syndax Pharmaceuticals is currently at the center of analytical scrutiny, with seven analysts providing insights into the com…
Syndax Pharmaceuticals: Navigating Diverse Analyst Perspectives on Innovation and Market Strategy Syndax Pharmaceuticals stands at a pivotal moment as analysts present a range of opinions on the compa…
Syndax Pharmaceuticals: Navigating Analysts' Divergent Views in Biotechnology Syndax Pharmaceuticals Inc. is currently in the spotlight as analysts express a spectrum of opinions regarding the company…
Syndax Pharmaceuticals: Navigating a Landscape of Mixed Analyst Sentiment Syndax Pharmaceuticals Inc. stands at a pivotal moment in the biotechnology sector, as recent analyst evaluations reflect a sp…
Syndax Pharmaceuticals: Navigating Mixed Analyst Sentiments Amidst Biotech Growth In recent weeks, Syndax Pharmaceuticals has drawn the scrutiny of five analysts, who present a spectrum of opinions on…
Syndax Pharmaceuticals: Advancing Cancer Treatment with Innovative Approaches Syndax Pharmaceuticals is at the forefront of developing novel therapies for cancer treatment, leveraging its unique exper…
Syndax Pharmaceuticals: Navigating R&D Expenses Amid Positive Revenue Trends Syndax Pharmaceuticals faces a pivotal moment as it releases its quarterly earnings report, revealing both challenges and o…
Syndax Pharmaceuticals: Navigating Research and Development Challenges Amidst Growth Syndax Pharmaceuticals is currently navigating a complex landscape as it reports a significant increase in its rese…
Syndax Pharmaceuticals Gears Up for Key Earnings Announcement Amid Promising Drug Development Syndax Pharmaceuticals is on the brink of announcing its quarterly earnings on August 4, 2025, a moment th…
Syndax Pharmaceuticals Gears Up for Earnings Announcement Amidst Promising Drug Development Pipeline Syndax Pharmaceuticals is poised to announce its quarterly earnings on August 4, 2025, a moment tha…
Syndax Pharmaceuticals Navigates Volatile Market Landscape Amidst Broader Economic Indicators Syndax Pharmaceuticals operates in a complex and rapidly evolving biotechnology landscape, where understan…
Syndax Pharmaceuticals: Navigating Industry Challenges Amid Market Volatility Syndax Pharmaceuticals is currently at a pivotal moment as it confronts the broader challenges in the biopharmaceutical la…
Syndax Pharmaceuticals Advances in Innovative Cancer Therapies Syndax Pharmaceuticals focuses on developing cutting-edge therapies for cancer treatment, particularly through its innovative pipeline ta…